Suppliers / Shandong Loncom Pharmaceutical

Shandong Loncom Pharmaceutical

China Updated 9 July 2026

Shandong Loncom Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 11 molecules.

11
active US DMFs
0
valid CEPs
0
registered plants
2
filings across 1 regulators

What they file, and where

Molecule Regulators Docs
Atomoxetine US FDA 1
Azilsartan Medoxomil US FDA 1
Dapoxetine US FDA 1
Daprodustat US FDA 1
Dotinurad US FDA 1
Elagolix US FDA 1
Ertugliflozin US FDA 1
Fezolinetant US FDA 1
Relugolix US FDA 1
Resmetirom US FDA 1
Show all 11 molecules on file
Vonoprazan US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None

Questions about Shandong Loncom Pharmaceutical

Does Shandong Loncom Pharmaceutical hold a US DMF or a CEP?
Shandong Loncom Pharmaceutical holds 11 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Shandong Loncom Pharmaceutical make?
11 molecules are on record against Shandong Loncom Pharmaceutical, including Atomoxetine, Azilsartan Medoxomil, Dapoxetine and Daprodustat. Each links through to that molecule's full manufacturer list.
Where does Shandong Loncom Pharmaceutical file?
Filings are on record with MINSA (CR), 2 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Shandong Loncom Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability